Preclinical validation of reconstructive/regenerative biomaterial for dentistry

• Grant number: 23/05736-7
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: October 01, 2023
• End date: June 30, 2024
• Field of knowledge: Interdisciplinary Subjects
• Principal Investigator: Matheus Henrique Romão
• Grantee: Matheus Henrique Romão
• CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais
• Associated researchers: Karina Fittipaldi Bombonato Prado
• Associated research grant(s): 25/01402-2 - In Vivo and In Vitro Approaches to Validate the Effectiveness of QMatrix, as a new reconstructive and regenerative biomaterial in dentistry, AP.PIPE
• Associated scholarship(s): 23/13555-2 - Use of QMatrix as a regenerative biomaterial for Dentistry, BP.TT; 23/13498-9 - Pre-clinical validation of reconstructive/regenerative biomaterial for Dentistry, BP.PIPE

Abstract

One of the scenarios of modern science that has stood out the most is regenerative medicine. The secretion of injured tissues can be done by combining cells and biomaterials that age as supports for cellular architecture, directing the growth of new tissue. These biomaterials need to be biocompatible and bioactive. Collagen-based biomaterials are a very promising choice as they offer support for cell adhesion, controllable mechanical properties and lower risk of immune reactions. Unfortunately, however, most collagens available on the market are of animal origin, being unsafe for human applications. One of the great niches that has expanded in regenerative studies is regenerative endodontics, where the importance of collagen has also been observed, and in which studies report the use of collagen I as a biomaterial that stimulates toothpaste cells. The extracellular matrix developed in a disruptive way by Quantis/Bioinn, the QMatrix, is composed mainly of type I collagen produced by primary human cells and without modified genetics, therefore, the final product is considered bioidentical to the human. In addition, all inputs are free of animal origin and the obtaining process does not have chemical or enzymatic components, which allows for a purer product, without the risk of microbiological, chemical or enzymatic contamination. Given its high degree of purity and biocompatibility, this collagen could be the ideal object of study for applications in regenerative endodontics. The biostimulating potential of QMatrix has already been verified in preliminary tests where an increase in cell experience and cell viability of human fibroblasts was observed, indicating the possibility of the matrix exerting tissue stimulation effects through cell stimulation. This project aims, through new in vitro tests, to validate the potential of QMatrix as a stimulating biomaterial, expanding Quantis' scope of action and entering the field of regenerative studies through dental applications, aiming at possible tests in patients in the future. The fact that the company already has collaborations and research partnerships with several institutes and universities inside and outside the country is a great catalyst for this project, as several studies are already being carried out in different cellular models and in vitro applications with QMatrix. However, there is the objective of strategically expanding the possibilities of short-term use of the QMatrix and, mainly, to carry out the first tests focusing on regenerative endodontics as a gateway to possible larger applications of tissue engineering and regenerative medicine. (AU)